Often when using nanoparticles to target and penetrate cancer cells, the shape of the tiny drug-carrying vehicles is crucial to their performance. Researchers have now found evidence that "worm-shaped" nanoparticles may be more effective than spheres at delivering cancer drugs to breast cancer.
Believe us when we tell you this: The 15 fiercest medical device and diagnostics companies of 2013 rival our first annual roundup from 2012 in terms of innovation, drive and market-changing technology.
This year's winners include a company that concocted a blood test to help spot autism earlier in children. Another developed a new device to fight obesity in a novel way, and a third came up with a novel ultrasound device to treat uterine fibroids. A fourth--a molecular diagnostics company with an extremely sensitive and precise thyroid cancer test--filed IPO plans a few weeks before this special report came out. That company's likely advance to the public market reflects a confidence about the game-changing ability of its new test, the market potential of other technology in its pipeline, and an educated guess that investors will want a piece of the action once it goes public. Read the full report >>
Treatment options currently available to diabetics are limited to imperfect solutions, as both patients and caretakers will attest. Painful, bulky, time-consuming insulin delivery methods abound, and the industry knows it. Therefore, the company that finds an all-in-one solution that makes life easier for patients with diabetes also knows there's a payday in store.
Cue the artificial pancreas. The drug delivery device--combining an insulin pump with a glucose monitor for complete, automated control over insulin dosage--has occupied the sights of several big names in the diabetes arena, giving rise to several iterations currently moving forward in clinical trials. But who is ready to land the coveted approval first? And is the technology effective enough to facilitate an immediate payoff? Check out the report >>
POPULAR COMMENT THREADS
Unilife is at it again. This time it's Novartis signing a deal with the injectable technology provider, adding to Unilife's impressive list of recent agreements with top pharmaceutical companies Sanofi, MedImmune and Hikma.
It looks like BioDelivery Sciences is on its way to a Phase III clinical trial of its topical gel treatment for painful diabetic neuropathy following a "positive" meeting with the FDA.
Tiny, programmed drug-delivery vehicles called nanorobots have the potential to bring about more targeted treatments with fewer side effects. And a research team has built the beginnings of a DNA-based cage capable of holding and releasing drugs in such a programmed way.
At the Georgia Institute of Technology and Emory University, researchers are looking for a new way to treat rotator cuff injuries, a common baseball shoulder ailment that has ended many a star pitcher's career.
The co-founders of Bind Therapeutics, which includes MIT professor and entrepreneur Robert Langer, published new data for its targeted nanoparticle platform called Accurins, which are designed to carry drugs to specific parts of the body to treat diseases.
After earlier this month announcing promising new data supporting its genetic treatment for hepatitis B, Arrowhead Research is moving forward with the candidate, submitting its application to begin a Phase IIa trial of ARC-520, which uses its polymer-based method to effectively deliver RNAi to the nucleus.
From Our Sister Sites
American, French and Cambodian researchers came up with two new diagnostic tests they say create quick and easy ways to detect malaria patients' resistance to a super-potent drug treatment. And those tests, in turn, should spur new drug-development efforts.
Genia Technologies has landed a $5.3 NIH grant to advance its genome sequencing technology. The company will use the money in its work with partners at Columbia University and Harvard Medical school to fund more development of NanoTag, its nanopore-based DNA sequencing platform.